Supporting this notion, various preclinical studies revealed that anti-VEGF therapy, either with anti-VEGF mAb or TKIs, could enhance the efficacy of different immunotherapies, leading to tumor regression and a prolonged animal survival phenotype [67,68]. Here, VEGFA is linked to neoplasm.